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Conclusion: After BMS implantation, stent fracture could have no effect on stent
thrombosis. However, stent fracture after DES implantation could have impact on stent
thrombosis as time passes.
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Background: Implantation of long and multiple overlapping DES in diffusely diseased
vessels, is frequently performed in routine clinical practice. Despite their widespread
use, concerns have been raised regarding DES safety and efficacy for treatment of
diffuse disease or long lesions requiring multiple stent implantation. In this registry,
we assessed the performance of the second generation Resolute Zotarolimus-eluting
stent (ZES) in this specific subgroup of patients.
Methods: From August 2008, 314 patients treated in 10 Italian Centers with >31.5mm
Resolute stent were prospectively followed in the context of the Clinical-Service
program. Comparison with patients receiving <31.5 mm of stents was also
performed.Patients were divided in two groups according to the length of the stent
implanted: group 1[(n=731)Short Stent, SS]: stented segment length≤ 31.5mm; group
2 [(n= 314) Long Stent, LS]: stented segment length >31.5mm. We compare the
incidence of MACE (cardiac death, re-myocardial infarction, TLR ), stent thrombosis
(ST) and target vessel revascularization (TVR) in the two groups.
Results: 314 patients(575 lesions) with a total ZES length >31.5 mm was collected in
the LS group (79% male, 66±10 years, 33% diabetic). The mean follow up was
244±160 days.SS group was composed of 731 patients (77% male, 65±11 years, 30%
diabetic) followed for a mean time of 316±295 days.There was no significant difference
in the overall incidence of MACE among the two groups (5.6% in LS versus 5.7% in
SS, p=ns).The incidence of cardiac death (1.8% vs. 2.5%), acute myocardial infarction
(2.8% vs. 2.6%), TLR (2.4% vs. 2.6%) and TVR (5.5% vs. 6.9%) was similar in the
long and short stent group (p=ns), respectively. No difference was found in ST between
the LS vs. SS groups (definite: 0.6% vs. 0.3%, p=0.37; probable: 0% vs. 1.4%,
p=0.27;early: 0.6% vs. 0.3%, p=ns; late: 0.6% vs. 2% p=ns). Dual antiplatelet therapy
discontinuation before 12 months was similar in the two groups (LS=1.6%, SS=2.9%,
p=ns).
Conclusion: In this multicentre prospective study, implantation of the Resolute ZES
for the treatment of diffuse and long coronary artery disease appears effective and safe.
Multiple or long Resolute stent implantation was associated with an acceptable MACE
rate at mid-to-long term follow-up without a significant increase in the risk of ST.
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Background: Since the approval of Drug-Eluting Stents (DES) in Europe in 2002,
DES have been quickly entering into daily clinical practice even in indications without
data from randomised controlled clinical trials (off-label use). At the European and
World Congress of Cardiology in Barcelona 2006, alarming data were presented on a
worse long-term prognosis following DES implantation compared with BMS. This
resulted in a higher cautiousness for its use with a decrease of DES implantations in
clinical practice.
Methods: Between 2005 and 2008, 47,407 consecutive patients undergoing PCI were
enrolled into the PCI-Registry of the Euro Heart Survey Programme to document
patient characteristics, PCI details and hospital complications in different PCI
indications. We examined the development of DES use over time by splitting the
enrolment period into 6- months periods (Jan-Jun and Jul-Dec) for the years 2005 to
2008 to identify a possible collapse in DES use and its further development following
September 2006.
Results: A total of 22,917 patients underwent elective PCI, 24,090 PCI for ACS. From
the very beginning of the documentation period the use of DES was high with about
60% in elective PCI and about 50% in PCI for ACS. After the presentation of the
alarming data on long-term outcome after DES during the ESC Congress in 2006, the
use of DES significantly decreased to 43% in elective PCI (p<0.01) and to 33% in PCI
for ACS (p<0.01) and remained low since then.
Conclusion: In consecutive patients undergoing elective PCI as well as PCI for ACS
in Europe, the use of DES collapsed after the presentation of alarming data of a worse
long- term prognosis following DES implantation during the ESC-Congress 2006.
Despite re-assuring data on the safety of DES, the use of DES did not recover in clinical
practice in Europe.
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Background: Efficacy and safety data following sirolimus-eluting stent (SES) PCI in
unselected patients at very long-term follow-up (>5 years) are still limited.
Methods: all consecutive patients with significant coronary artery stenosis treated with
PCI and only SES implantation between December 2001 and February 2003 were
analyzed in order to assess the survival-free from major adverse cardiovascular events
(MACE) defined as a composite of death, myocardial infarction (MI) and target vessel
revascularization (TVR) and survival-free from target lesion failure (TLF) defined as
a composite of cardiac death, target vessel-MI (TV-MI) and target lesion
revascularization (TLR).
Results: 447consecutive patients (954 lesions) treated with SES implantation were
treated in the study period. Mean age was 61.9±10.4 years, 399 (89.3%) patients were
male, 99 (22.1%) had diabetes mellitus, and 356 (79.6%) had multi-vessel disease. Of
the 954 lesions treated, 771 (80.8%) were ACC/AHA type B2/C including ostial
(19.5%), bifurcation (18.6%), restenotic (16.2%), chronic total occlusions (9.9%) and
left main (9.1%) lesions. Mean number of stents implanted per patients was 2.03 ±
1.04. Median dual antiplatetlet therapy (DAT) duration was 253 (IQR 162-1197) days.
Clinical follow-up was available at 8 years in 403 eligible patients (90.2%). The
cumulative incidence of events at 8 years was: death 15.7% (65 patients), cardiac death
8.3% (34 patients); MI 7.9% (32 patients), TV-MI 6.2% (25 patients) and TVR 41.2%
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